Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552461 · ClinicalTrials.gov registry record · Phase 2
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
A Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease, sponsored by East Carolina University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00552461: Completed Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease, sponsored by East Carolina University.
NCT00552461 is a Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease that has completed, run by East Carolina University. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00552461, a Phase 2 study of Pulmonary Alveolar Proteinosis and Primary Disease, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.
Conditions Studied
Interventions
- DRUG rituximab
Study Locations (1)
North Carolina
- East Carolina University - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00552461 record still lists
NCT00552461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Pulmonary Alveolar Proteinosis appearing as the primary indexed condition, and to 1 intervention - of which rituximab is the first listed.
NCT00552461 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00552461 about?
NCT00552461 is a clinical study titled "Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis". The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.
What is the current status of trial NCT00552461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-01. Estimated completion is 2011-12.
What conditions does trial NCT00552461 study?
This clinical trial studies the following conditions: Pulmonary Alveolar Proteinosis, Primary Disease.
What interventions are being tested in trial NCT00552461?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT00552461?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552461 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Alveolar Proteinosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00552461's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia